APTOF — what changed in the latest 10-Q
A section-by-section comparison of APTOF's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-13 vs the prior 10-Q · 2025-11-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +105 | −180 | ~36 | 190 |
| Controls & procedures | Text added/removed | +105 | −180 | ~36 | 189 |
| Legal proceedings | Text added/removed | +105 | −180 | ~36 | 189 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-13
the Arrangement and its expected terms, benefits, timing and closing, including satisfaction of customary closing conditions, and the anticipated timing thereof;
We are advancing targeted agents to treat life-threatening hematologic cancers that require immediate treatment. We have one clinical-stage oral kinase inhibitor under active development for the treatment of hematological malignancies: tuspetinib.
As discussed in Note 7 below, on November 18, 2025, the Company entered into an Arrangement Agreement, as amended on February 23, 2026, to which Hanmi Purchaser will acquire all of the issued and outstanding Common Shares of the Company that are not currently owned or controlled by the Hanmi Purchas…
Restricted cash consists of deposits in operating accounts and reflects the balance of unspent proceeds associated with the loan payable to related party. As of March 31, 2026, the restricted cash balance was $3.1 million (December 31, 2025 - $3.2 million).
On August 27, 2024, the Company and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) entered into a loan agreement, pursuant to which Hanmi agreed to loan $10.0 million to the Company (the “Hanmi Loan Agreement”). Under the terms of the Hanmi Loan Agreement, the loan proceeds are restricted in their use and …
Text removed vs the prior filing · source: 10-Q · 2025-11-13
For the three and nine months ended September 30, 2025 and 2024
Shares and warrants issued under the Registered Direct Offering
Common shares and warrants issued pursuant to the Hanmi Private Placement
Common shares and warrants issued pursuant to the January 2024 Public Offering
Common shares issued under the 2023 Committed Equity Facility
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-05-13
the Arrangement and its expected terms, benefits, timing and closing, including satisfaction of customary closing conditions, and the anticipated timing thereof;
We are advancing targeted agents to treat life-threatening hematologic cancers that require immediate treatment. We have one clinical-stage oral kinase inhibitor under active development for the treatment of hematological malignancies: tuspetinib.
As discussed in Note 7 below, on November 18, 2025, the Company entered into an Arrangement Agreement, as amended on February 23, 2026, to which Hanmi Purchaser will acquire all of the issued and outstanding Common Shares of the Company that are not currently owned or controlled by the Hanmi Purchas…
Restricted cash consists of deposits in operating accounts and reflects the balance of unspent proceeds associated with the loan payable to related party. As of March 31, 2026, the restricted cash balance was $3.1 million (December 31, 2025 - $3.2 million).
On August 27, 2024, the Company and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) entered into a loan agreement, pursuant to which Hanmi agreed to loan $10.0 million to the Company (the “Hanmi Loan Agreement”). Under the terms of the Hanmi Loan Agreement, the loan proceeds are restricted in their use and …
Text removed vs the prior filing · source: 10-Q · 2025-11-13
For the three and nine months ended September 30, 2025 and 2024
Shares and warrants issued under the Registered Direct Offering
Common shares and warrants issued pursuant to the Hanmi Private Placement
Common shares and warrants issued pursuant to the January 2024 Public Offering
Common shares issued under the 2023 Committed Equity Facility
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-05-13
the Arrangement and its expected terms, benefits, timing and closing, including satisfaction of customary closing conditions, and the anticipated timing thereof;
We are advancing targeted agents to treat life-threatening hematologic cancers that require immediate treatment. We have one clinical-stage oral kinase inhibitor under active development for the treatment of hematological malignancies: tuspetinib.
As discussed in Note 7 below, on November 18, 2025, the Company entered into an Arrangement Agreement, as amended on February 23, 2026, to which Hanmi Purchaser will acquire all of the issued and outstanding Common Shares of the Company that are not currently owned or controlled by the Hanmi Purchas…
Restricted cash consists of deposits in operating accounts and reflects the balance of unspent proceeds associated with the loan payable to related party. As of March 31, 2026, the restricted cash balance was $3.1 million (December 31, 2025 - $3.2 million).
On August 27, 2024, the Company and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) entered into a loan agreement, pursuant to which Hanmi agreed to loan $10.0 million to the Company (the “Hanmi Loan Agreement”). Under the terms of the Hanmi Loan Agreement, the loan proceeds are restricted in their use and …
Text removed vs the prior filing · source: 10-Q · 2025-11-13
For the three and nine months ended September 30, 2025 and 2024
Shares and warrants issued under the Registered Direct Offering
Common shares and warrants issued pursuant to the Hanmi Private Placement
Common shares and warrants issued pursuant to the January 2024 Public Offering
Common shares issued under the 2023 Committed Equity Facility
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice